Is ankylosing spondylitis associated with pulmonary complications?

Ankylosing Spondylitis and Pulmonary Complications

Yes, ankylosing spondylitis is definitively associated with multiple pulmonary complications, including restrictive lung disease, apical fibrosis, interstitial lung disease, obstructive sleep apnea, and spontaneous pneumothorax. 1, 2

Primary Pulmonary Manifestations

The pulmonary involvement in AS is well-established and clinically significant:

• Restrictive lung disease is the most prevalent pulmonary complication, occurring in approximately 18% of AS patients compared to 0% in matched controls 3
• Apical pulmonary fibrosis represents a classic but less common manifestation, affecting the upper lung lobes specifically 1, 4
• Interstitial lung disease can develop as part of the inflammatory process 2, 4
• Obstructive sleep apnea has emerged as a recognized association, though the exact prevalence requires further study 1, 2
• Spontaneous pneumothorax occurs with increased frequency in AS patients 1, 4

Mechanism of Restrictive Impairment

The restrictive ventilatory pattern in AS has a clear mechanical basis:

• Reduced spinal mobility (measured by BASMI) directly correlates with decreased forced vital capacity (FVC%), with spinal mobility, chest expansion, and male gender explaining 45% of the variance in FVC% 3
• Chest wall restriction from ankylosis of costovertebral and costotransverse joints mechanically limits lung expansion 1, 4
• This represents a musculoskeletal limitation rather than primary parenchymal disease in most cases 3

Early Detection Considerations

Pulmonary abnormalities can precede clinical symptoms:

• Multidetector CT (MDCT) detects abnormalities in 96.87% of early AS patients, even in asymptomatic individuals with normal pulmonary function tests 5
• The most common MDCT findings include nodules, peribronchial thickening, pleural thickening, and bronchiectasis 5
• MDCT screening may be beneficial even in asymptomatic patients without PFT abnormalities, particularly in early disease stages 5

Clinical Management Implications

The pulmonary complications directly impact treatment strategy:

• Maintaining spinal flexibility is critical to prevent progressive restrictive lung disease, as reduced spinal mobility is the primary driver of ventilatory impairment 3
• Patients with severely reduced spinal mobility should undergo pulmonary function testing and receive appropriate respiratory follow-up 3
• Anterior chest wall pain is a common presenting symptom that may indicate early restrictive changes 1

Medication-Related Pulmonary Risks

Treatment itself carries pulmonary considerations:

• Medications used to treat AS (including biologics) can cause pulmonary complications such as infections, pneumonitis, and rarely serositis 1
• This adds complexity to distinguishing disease-related from treatment-related pulmonary manifestations 1

Screening Gaps

Despite well-documented associations, systematic screening remains inconsistent:

• No clear guidelines exist for stepwise cardiovascular and pulmonary screening in AS populations 4
• Given the high prevalence of restrictive disease and early MDCT abnormalities, routine pulmonary assessment should be considered in AS management, particularly for patients with reduced spinal mobility or chest expansion 5, 3